ideasIdea
A blood test for the pre-metastatic niche
Before cancer spreads, distant organs are changed to become welcoming. A test for those changes would show which organ is at risk while a person still looks cancer-free.
Pre-metastatic niche formation involves tumour-derived exosome integrins, S100A8 and S100A9 induction, myeloid mobilisation and fibronectin deposition in the target organ. Candidate readouts exist — plasma S100A8/A9, exosomal integrin profiles, circulating LOX activity, neutrophil trajectories — but nobody has assembled them into a validated organ-specific risk assay.
Hypothesis
A multi-analyte niche score measured after curative surgery predicts organ-specific relapse (lung versus liver versus bone) with a c-statistic above 0.75, independently of and additively to ctDNA.
Rationale
Exosomal integrin patterns predicted lung and liver organotropism respectively in mouse and human samples. Organ-specific prediction would let prevention be targeted to one organ, which a single ctDNA yes-or-no answer cannot do.
What would test it
Nested case-control study in two existing adjuvant trial biobanks with known relapse sites; lock the score, then validate it prospectively in a third cohort.
Maturity
speculative
Who has to act
research
Cost to try
Medium ($1M to $50M)
Years to first evidence
7
Bottlenecks it attacks
- Metastasis is understood least and studied last · Metastasis causes about nine in ten cancer deaths but gets a small fraction of research money and almost no trials of its own.
- Dormant cells and minimal residual disease · After a 'successful' treatment, cells can sleep for years then relapse. We can barely detect them and cannot target them.
- Biomarkers are not validated or standardised · Tests that decide who gets a drug are often not validated prospectively and are measured differently in every lab.